Medication use patterns in pregnant women with psoriasis: a nationwide study in Taiwan
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Chien-Hua Ou und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, National Defense Medical Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Psoriasis, Pregnancy Complications. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Background
Psoriasis, an autoimmune skin condition, affects 2–4% of the global population, with significant prevalence among women of childbearing age. Pregnancy presents challenges in managing psoriasis because of hormonal changes and treatment safety concerns. Understanding treatment patterns in pregnant women is crucial, given limited real-world evidence.
Objectives
To explore the utilization patterns of medications among pregnant women diagnosed with psoriasis within real-world data, utilizing data sourced from a nationwide database in Taiwan.
Methods
This nationwide study utilized Taiwan's National Health Insurance (NHI) database and birth certificate application records. It included registered pregnant women diagnosed with psoriasis from 2005 to 2014. Medication usage was tracked 3 years before conception to 3 years after delivery. Medications were categorized based on Anatomical Therapeutic Chemical codes, and statistical analyses were conducted using SAS software.
Results
In total, 30 267 pregnant women with psoriasis were studied. In total, 11 651 (38.5%) mothers had received ≥ 1 prescription during follow-up (exposed group) and 61.5% (18 616) had never received medication (unexposed group). Demographics and comorbidities were similar between these two groups. Topical corticosteroids were the most prescribed treatment, followed by phototherapy, with systemic drugs and biologics less common. During the study period, 11 096 women with psoriasis had used topical corticosteroids, 3376 had used nonsteroidal topical agents, 218 had used systemic agents or biologics and 519 had received treatment with phototherapy. Medication usage declined during pregnancy, reaching its lowest in the third trimester but rebounded postpartum.
Conclusions
Psoriasis medications, systemic, biological or topical, were largely discontinued during pregnancy, sometimes up to 2 years before and extending postpartum. Research is needed to understand its impact on maternal and child health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
- Department of Clinical Pharmacy, Tri-Service General Hospital Penghu Branch, Penghu, Taiwan.
- Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan.
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
- School of Public Health, National Defense Medical Center, Taipei, Taiwan.
- Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
ORCID-Profile: Li-Ting Kao
Förderung
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Ou, C. H., Kao, L. T., Yang, H. W., Chiang, Y. L., Wen, Y. L., To, S. Y., & Chen, Y. H. (2024). Medication use patterns in pregnant women with psoriasis: a nationwide study in Taiwan. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae260
Vancouver
Ou CH, Kao LT, Yang HW, Chiang YL, Wen YL, To SY, et al. Medication use patterns in pregnant women with psoriasis: a nationwide study in Taiwan. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae260
BibTeX
@article{Ou2024,
author = {Ou, Chien-Hua and Kao, Li-Ting and Yang, Hui-Wen and Chiang, Yi-Lin and Wen, Yuan-Liang and To, Sheng-Yin and Chen, Yi-Hsien},
title = {Medication use patterns in pregnant women with psoriasis: a nationwide study in Taiwan},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae260}
}
EUVIMED